Matching with our results, promoter hypermethylation was reported to inactivate CDKN2A in sporadic parathyroid adenomas [63], breast cancer [64], periocular sebaceous carcinoma [65], and hepatocellular carcinoma [66]. This evidence concerns the gene CDKN2A and breast cancer.